Rebound in travel helps vaccine maker Valneva post smaller-than-expected loss

(Reuters) – French vaccine maker Valneva reported on Thursday a smaller-than-expected first-quarter loss as sales of travel vaccines Dukoral and Ixiaro improved, propelling its shares 16% up. Valneva also confirmed its sales outlook for 2023, with revenue expected between 220 million euros and 260 million euros. “We managed to double our first-quarter vaccine sales year-over-year, keeping us on track to deliver on our full-year sales guidance,” Chief Financical Officer Peter Bühler said in a results statement. After the European Commission dropped nearly all of its orders of 60 million doses o…

Read More